Literature DB >> 16261445

Current status of monoclonal antibodies as therapeutic agents for solid cancer.

Chiaki Okuse, Fumio Itoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16261445     DOI： 10.1007/s00535-005-1699-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  18 in total

Review 1.  Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic.

Authors:  John Mendelsohn
Journal:  Cancer Immunol Immunother       Date:  2003-03-14       Impact factor: 6.968

2.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors:  H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

3.  A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.

Authors:  James A Posey; Thian C Ng; Baolian Yang; M B Khazaeli; Mark D Carpenter; Floyd Fox; Mike Needle; Harlan Waksal; Albert F LoBuglio
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

4.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.

Authors:  Roy S Herbst; Dong M Shin
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

7.  Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

Authors:  H Safran; M Steinhoff; S Mangray; R Rathore; T C King; L Chai; K Berzein; T Moore; D Iannitti; P Reiss; T Pasquariello; P Akerman; D Quirk; R Mass; L Goldstein; U Tantravahi
Journal:  Am J Clin Oncol       Date:  2001-10       Impact factor: 2.339

8.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions.

Authors:  Kanenori Endo; Byung-Il Yoon; Chawalit Pairojkul; Anthony J Demetris; Alphonse E Sirica
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

10.  Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product.

Authors:  T Ishida; M Tsujisaki; Y Hinoda; K Imai; A Yachi
Journal:  Jpn J Cancer Res       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.